# Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers

> **NCT00996671** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 38 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2256098
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00996671
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-06
- **Primary completion:** 2010-03-17
- **Final completion:** 2010-03-17
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996671, "Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00996671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*